NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC

By December 16, 2014

NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) reported that between December 2 and 12, 2014, NovaBay’s CEO, CFO and Senior Vice President have filed Form 4’s with the Security and Exchange Commission reporting their combined purchases of 143,000 shares of NovaBay common stock in open market purchases.  During one the company’s infrequent and brief open trading windows for insiders, NovaBay’s CEO, Dr. Ron Najafi, purchased over 113,000 shares, the Company’s CFO, Tom Paulson, purchased 20,000 shares and NovaBay’s Senior Vice President of Ophthalmology, Dr. David Stroman, purchased 10,000 shares.  Shares were purchased at prices ranging between $0.60 and $0.71; prices the Officers believe are a substantial discount to NovaBay’s potential long term value.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®?
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its FDA cleared Neutrox™ Family of Products: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™ for the dermatology market.

Forward-looking Statements?

This release contains forward-looking statements which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. Statements in this press release which are not a plain recitation of fact should be considered forward looking statements. This press release shall not constitute an offer to sell, or the solicitation of an offer, to buy or sell securities. Risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact T. Paulson

TOP